Life of Riley at Adeona with new CEO, CFO and directors
This article was originally published in Scrip
Adeona Pharmaceuticals, a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, has appointed its chair, Jeff Riley, president and CEO. Mr Riley has been a director at Adeona since 2010 and chair since November 2011. He most recently served as managing director of 526 Ventures.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.